Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease
Eligibility for device-aided therapy is common but underutilised. These findings highlight missed opportunities and support earlier, genotype-informed treatment planning in Parkinson's disease.
Authors
- Debra Galley
- Charlotte B. Stewart
- Nicola Pavese
- Rachel Iredale
- David Ledingham (ORCID: https://orcid.org/0000-0002-6474-2666)
- Victoria Foster (ORCID: https://orcid.org/0000-0002-9391-245X)
- Mark R. Baker (ORCID: https://orcid.org/0000-0001-6916-1329)
- Sahana Sathyanarayana
Institutions
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Aarhus University Hospital (DK)
- Newcastle Hospitals - Campus for Ageing and Vitality (GB)
- Newcastle University (GB)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1002/acn3.70188
- Primary Topic
- Neurological disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Jazz Pharmaceuticals
- Neurocrine Biosciences
- Verily Life Sciences
- Newcastle University
- Newcastle upon Tyne Hospitals NHS Foundation Trust
- Servier
- H. Lundbeck A/S
- Sun Pharma
- Genentech
- Allergan
- Avid Radiopharmaceuticals